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Point mutations in ‘‘myelin genes’’ result in a spectrum of inherited demyelinating neuropathies. The under-
standing of the pathomechanisms by which these mutations produce phenotypes remains limited. In this
issue of Neuron, Wrabetz and colleagues report that the unfolded protein response (UPR) is responsible
for demyelination in a Charcot-Marie-Tooth disease type 1B (CMT1B) mouse model. Deletion of the UPR
mediator transcription factor CHOP completely rescues the motor deficit and ameliorates the neuropathy
phenotype.The molecular cause of demyelinating
Charcot-Marie-Tooth (CMT1; [OMIM
118200]) disease in 70% of patients is
a duplication of a 1.4 Mb region on the
short arm of chromosome 17 that includes
the dosage-sensitive peripheral myelin
protein 22 gene (PMP22). The reciprocal
deletion of the same region is associated
with a milder disease, hereditary neuropa-
thy with liability to pressure palsies (HNPP;
[OMIM 162500]). Both human studies and
animal models reveal that alteration in
PMP22 gene dosage and expression has
profound consequences for the devel-
opment and maintenance of peripheral
nerves, suggesting that subtle alteration
in synthesis, processing, or degradation
can underlie the neuropathy disease pro-
cess (Lupski and Chance, 2005). Conse-
quently, the regulation of PMP22 gene ex-
pression has been the focus of therapeutic
strategies for CMT1A (Sereda et al., 2003;
Passage et al., 2004). However, these
therapeutic approaches are not feasible
for other genetic causes of CMT because
such molecular strategies apply only to
PMP22 overexpression.
Mutations in a multitude of different
genes, 27 identified thus far, can cause
CMT and related peripheral neuropathy
disorders. Heterozygous point mutations
of several of these genes, such as
PMP22 and Myelin Protein Zero (P0), con-
vey dominant traits including Dejerine-
Sottas neuropathy (DSN; [OMIM 145900])and congenital hypomyelinating neuropa-
thy (CHN; [OMIM 605253]), suggesting
that the pathomechanism for such muta-
tions may be gain of function, although
haploinsufficiency can also cause disease
as evidenced by the deletion of PMP22
causing HNPP (Lupski and Chance,
2005), and nonsense/frameshift alleles
in P0 that cause CMT1B (Inoue et al.,
2004). Previous studies have shown that
some mutant P0 and PMP22 aggregates
colocalize with BiP, an HSP70 chaperone
in the lumen of the endoplasmic reticulum
(ER) (Matsuyama et al., 2002; Shames
et al., 2003). The involvement of mutant
proteins with BiP is often hypothesized
to result in activation of the unfolded
protein response (UPR).
In an exciting study in this issue of Neu-
ron, Wrabetz and colleagues extended
their previous study in P0S63del mice
(a CMT1B model; Wrabetz et al., 2006)
and provide direct evidence of UPR ac-
tivation in S63del transgenic Schwann
cells (Pennuto et al., 2008). Deletion of
S63 in the extracellular domain of P0
causes CMT1B in humans, and the orthol-
ogous mutation in mice results in a similar
clinical and neuropathologic phenotype
(Wrabetz et al., 2006). Mutant P0S63del
is retained in the ER, triggering the UPR
as evidenced by significant changes in
the UPR markers BiP and CHOP and
Downstream of CHOP genes (DOCs)
(Pennuto et al., 2008). Three key ER-resi-Neurondent transmembrane proteins (IRE-1,
PERK, and ATF6), representing different
arms of UPR, were shown to be activated.
Interestingly, after breeding P0S63del
mice to CHOP-deficient (Chop/) ani-
mals, the S63 del-induced motor deficit
was rescued, suggesting that CHOP ‘‘tar-
get genes,’’ as part of a ‘‘maladaptive
stress response’’ in Schwann cells, di-
rectly cause demyelination. This suppres-
sion of the clinical disease phenotype is
supported by rescue of delayed F-waves,
neuromuscular changes associated with
demyelination, and motor capacity in the
P0S63del/Chop/ animals. Beautiful mo-
lecular/cellular biological experiments,
which alter the hydrophobicity of the P0
b strand C, support the contention that
protein misfolding, and not alteration of
side chain residues, results in ER reten-
tion and UPR activation.
An irony of UPR is that the response
leads to the simultaneous activation of
both adaptive and proapoptotic path-
ways. How can the UPR be a primarily
adaptive pathway under certain condi-
tions? Ablation of Chop partially protects
cells from ER-stress-mediated cell death
(Zinszner et al., 1998), and the mechanism
by which CHOP leads to cell death is not
yet known. As a transcription factor,
CHOP itself is not intrinsically apoptotic,
and it more likely affects the expression
of downstream genes, such as GADD34,
that may facilitate cell death. Thus, it will57, February 7, 2008 ª2008 Elsevier Inc. 329
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scriptional targets of CHOP such as
GADD34 in CMT mouse models. P0-trun-
cating mutants that are associated with
the more severe, childhood-onset DSN
and CHN have been shown to accumulate
primarily within the ER and induce apo-
ptosis (Khajavi et al., 2005). Facilitation
of the processing of such mutants from
the ER into the cytoplasm is accompanied
by a lower number of apoptotic cells
(Khajavi et al., 2005). It is intriguing that
Wrabetz and colleagues found that the
relative amounts of BiP and CHOP dif-
fered as a function of the dosage of the
S63del expression. They interpreted the
increased levels of CHOP in the face of
stable BiP that accompanied increased
S63del mutant expression as potentially
representing a transition from cell survival
to an apoptotic response. These latter ex-
periments again clearly stress how impor-
tant dosage of both normal and mutant
myelin proteins can be to dysfunction of
the peripheral nerve.
Accumulation of Pmp22 mutant Trem-
bler-J (Tr-J) and Trembler can also po-
tentially trigger ER stress, resulting in
Schwann cell death by apoptosis and,
subsequently, causing peripheral neurop-
athy (Sancho et al., 2001; Khajavi et al.,
2007). Although the mechanism through
which the processing and function of mis-
folded or aggregated PMP22Tr-J mutant
proteins in cells can be associated with
apoptosis has not yet been determined,
it is hypothesized that it may include inter-
ference with the function of the ER chap-
erones. Wild-type PMP22 and mutant
Tr-J protein form a complex with calnexin,
indicating that the sequestration of cal-
nexin might contribute to the disease
mechanism by affecting the pathway
that controls protein folding (Dickson
et al., 2002). In addition, retention of
mutant PMP22 in the ER and formation
of a complex with calnexin may instead
compromise the ability of calnexin to re-
tain GD3 synthase (ST8), a key com-
ponent for ceramide-induced apoptosis
(Tomassini et al., 2004), thus sensitizing
the cells to apoptosis. Small molecule
compounds that may promote selective330 Neuron 57, February 7, 2008 ª2008 Elsand specific alteration of the calcium
levels in the ER, or inhibition in any com-
ponent within the ER stress pathway,
have been shown to relieve the toxic ef-
fectsassociated withdisease-causing mu-
tations and reverse the potential defect
observed in misfolding mutants (Khajavi
et al., 2007).
Many diseases are linked to the accu-
mulation of proteins in the ER, suggesting
that misfolding often occurs in that com-
partment. Protein misfolding can contrib-
ute to disease through different mech-
anisms. Disease may result when the
efficiency of productive folding/traffick-
ing is reduced to a point at which there is
not enough properly trafficked, functional
protein to maintain normal physiological
function (loss-of-function mechanism). Al-
ternatively, the mechanism could be gain-
of-function, in which the aberrant protein
actively promotes disease due to changes
in normal protein or formation of toxic
aggregates such as amyloid (Yang et al.,
2004). Additionally, misfolded proteins
can accumulate to a level wherein ER-
associated degradation (ERAD) gets over-
whelmed, resulting in oversaturation of the
components of ERAD. For example, the
myelin proteolipid protein is produced in
vast quantities by myelinating oligoden-
drocytes. Abnormal amounts of mutant
proteolipid proteins in the ER can over-
whelm both ERAD and normal export
pathways, provoking the UPR and major
changes in cell physiology that are closely
linked to Pelizaeus-Merzbacher disease
(PMD [OMIM 312080]), a CNS dysmyeli-
nating disorder.
It is important to understand the differ-
ences in how various myelin gene mutant
proteins interact with the protein quality
control machinery, because this could
provide the basis for determining which
chemical chaperone therapeutic strate-
gies might be useful for specific protein
folding disorders. Rational drug design
could be based on different principles,
such as interfering with chaperone activity
and allowing misfolded proteins to make
their way out of the ER, or involving up-
regulation at the transcriptional level
and modulation of protein folding steps.evier Inc.Wrabetz and colleagues provide us with
additional insights into the myriad of po-
tential cellular pathomechanisms underly-
ing inherited peripheral neuropathy.
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